Download Files:
RG2833
$60 – $950
Products Details
Product Description
– RG2833 is a brain-penetrant HDAC inhibitor with IC50s of 60 nM and 50 nM for HDAC1 and HDAC3, respectively. The Ki values for HDAC1 and HDAC3 are 32 and 5 nM, respectively[1].
Web ID
– HY-16425
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C20H25N3O2
References
– [1]Johnston TH, et al. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study. Parkinsonism Relat Disord. 2013, 19(2), 260-264.|[2]Sandi C, et al. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol Dis. 2011, 42(3), 496-505.|[3]Rai M, et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich’s ataxia patients and in a mouse model. PLoS One. 2010, 5(1), e8825.
CAS Number
– 1215493-56-3
Molecular Weight
– 339.43
Compound Purity
– 99.86
SMILES
– O=C(NCCCCCC(NC1=CC=CC=C1N)=O)C2=CC=C(C)C=C2
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : ≥ 50 mg/mL
Target
– HDAC
Isoform
– HDAC1;HDAC3
Pathway
– Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
